OSE Immunotherapeutics SA (FRA:6OP)

Germany flag Germany · Delayed Price · Currency is EUR
5.31
+0.07 (1.43%)
At close: Nov 28, 2025
-39.86%
Market Cap118.49M
Revenue (ttm)83.44M
Net Income (ttm)37.45M
Shares Outn/a
EPS (ttm)1.46
PE Ratio3.16
Forward PE5.98
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume25
Open5.31
Previous Close5.24
Day's Range5.31 - 5.31
52-Week Range4.80 - 8.92
Betan/a
RSI42.33
Earnings DateDec 24, 2025

About OSE Immunotherapeutics

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2012
Employees 64
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 6OP
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.